Fulcrum Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Alan Ezekowitz

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Alan Ezekowitz”): 52,317,282 for, 1,471,820 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,169,393 for, 325,999 withheld, 3 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Colin Hill

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Colin Hill”): 52,363,595 for, 1,425,507 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,174,462 for, 320,929 withheld, 3 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Sonja Banks

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Sonja Banks”): 43,187,717 for, 10,601,385 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 8,728,837 for, 766,541 withheld, 17 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: A non-binding advisory vote to approve the compensation of our named executive officers;

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”): 50,735,617 for, 3,026,397 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “b) Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Fulcrum Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, no shares for or against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 50 managers: 9,324,755 for, 156,309 against, 14,329 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 130 managers: 33,561,719 for, 2,909,380 against, 10,158 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 58,793,645 for, 36,178 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “d) Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,481,011 for, 55 against, 14,329 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.